Angiotensin converting enzyme (ACE) levels
Pro Research Analysisby 
Searched over 200M research papers
Genetic Determinants of Angiotensin Converting Enzyme (ACE) Levels
Research shows that ACE levels are strongly influenced by genetic factors. Genome-wide association studies (GWAS) have identified 14 key genetic loci, mainly in the 17q23.3 and 9q34.2 regions, that are associated with ACE levels and activity. Many of these genetic variants also affect lipid and carbohydrate metabolism, immune function, and organ health, linking them to diseases such as cardiovascular disease, type 2 diabetes, and COVID-19. Notably, certain polymorphisms in the ABO gene (9q34.2) have significant effects on ACE levels and related health risks .
A specific insertion/deletion (I/D) polymorphism in the ACE gene accounts for nearly half of the variation in serum ACE levels among individuals. People with different genotypes for this polymorphism show marked differences in their ACE concentrations, making this genetic marker useful for distinguishing between normal and abnormal ACE levels 238. The I/D polymorphism and other genetic variants together explain a large portion of the variability in ACE levels, with the I allele generally associated with lower ACE concentrations 38.
ACE Levels in Health and Disease
Cardiovascular and Kidney Disease
ACE plays a central role in blood pressure regulation and is involved in the development and progression of cardiovascular and kidney diseases. Higher plasma ACE levels, influenced by genetic polymorphisms, are linked to increased risk of atherosclerotic cardiovascular disease and cardiovascular mortality, especially in patients with chronic kidney disease 168.
Obesity and Weight Loss
ACE levels are also associated with obesity. Studies have found that ACE can serve as an early marker for weight loss, with reductions in ACE levels correlating with weight loss after just one day of dieting, particularly in individuals with higher BMI .
Sarcoidosis and Other Lung Diseases
ACE is produced by activated alveolar macrophages and is often elevated in patients with active sarcoidosis, making it a useful, though not highly specific, biomarker for this disease. ACE levels tend to normalize with steroid treatment or disease resolution. However, ACE levels are generally lower in other chronic lung diseases and in patients receiving corticosteroids 79. The use of ACE inhibitors in sarcoidosis patients can lower ACE levels, and the choice of specific ACE inhibitor can influence the degree of reduction .
Tissue-Specific Regulation of ACE
ACE activity is regulated differently in various tissues. While serum ACE levels are influenced by genetic factors such as the I/D polymorphism, ACE expression in lung tissue does not show the same genotype dependence. There is a correlation between serum and heart tissue ACE activity, but not between serum and lung tissue ACE, suggesting tissue-specific regulation mechanisms. Endogenous inhibitors and secretion processes also play a role in controlling ACE activity in different organs .
Broader Physiological and Pathological Roles
Beyond its role in blood pressure regulation, ACE is involved in many physiological processes in organs such as the lungs, brain, pancreas, and liver. It is implicated in the pathogenesis of several diseases, including COVID-19, and is a target for widely used medications like ACE inhibitors and angiotensin receptor blockers .
Conclusion
ACE levels are primarily determined by genetic factors, especially polymorphisms in specific genome regions. These genetic influences have significant implications for cardiovascular, kidney, and metabolic diseases, as well as for conditions like sarcoidosis and obesity. ACE levels are regulated differently in various tissues and are affected by both genetic and non-genetic factors, including medication use. Understanding these determinants is crucial for using ACE as a biomarker and for optimizing disease management strategies.
Sources and full results
Most relevant research papers on this topic